- Home
- ZYME vs DBRG Comparison
ZYME vs DBRG Comparison
Compare ZYME & DBRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZYME | DBRG |
|---|---|---|
| Founded | 2003 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZYME | DBRG |
|---|---|---|
| Price | $23.23 | $15.45 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 7 |
| Target Price | ★ $32.75 | $16.00 |
| AVG Volume (30 Days) | 484.1K | ★ 3.4M |
| Earning Date | 03-30-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 0.26% |
| EPS Growth | ★ 5.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $76,304,000.00 | N/A |
| Revenue This Year | $63.10 | $373.39 |
| Revenue Next Year | $93.26 | $8.23 |
| P/E Ratio | ★ N/A | $252.25 |
| Revenue Growth | ★ 0.38 | N/A |
| 52 Week Low | $9.03 | $6.41 |
| 52 Week High | $28.49 | $15.55 |
Technical Indicators
Market Signals| Indicator | ZYME | DBRG |
|---|---|---|
| Relative Strength Index (RSI) | 49.13 | 63.70 |
| Support Level | $22.22 | $15.32 |
| Resistance Level | $23.66 | $15.47 |
| Average True Range (ATR) | 0.84 | 0.06 |
| MACD | 0.15 | -0.05 |
| Stochastic Oscillator | 45.85 | 79.17 |
Price Performance
Historical ComparisonAbout ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About DBRG DigitalBridge Group Inc.
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centres, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.